

EQA Schemes Catalogue and Participant Guide 2025

ERNDIM Administration Office c/o EMQN CIC, Unit 4, Enterprise House, Manchester Science Park, Pencroft Way, Manchester, M15 6SE, United Kingdom Tel: +44 161 757 4952 Fax: +44 161 850 1145 E-mail: admin@erndim.org Web: www.erndim.org

European Research Network for evaluation and improvement of screening, Diagnosis and treatment of Inherited disorders of Metabolism

Contents

1. Introduction		3	
2. EQA Schemes		4	
2.1. Quantit	ative Schemes	4	
ACS	Acylcarnitines in Serum	4	
PPU	Purines and Pyrimidines (urine)	4	
QTAS	Quantitative Amino Acids (serum)	5	
QTOU	Quantitative Organic Acids (urine)	5	
SADB	Special Assays in dried blood spots	5	
SAS	Special Assays in Serum	6	
SAU	Special Assays in Urine	6	
SAC	Special Assays Combined (serum & urine)	6	
2.1.1. Q	uantitative EQA Schemes' summary	7	
2.2. Hybrid	Schemes	8	
CWBC	Cystine in White Blood Cells	8	
LEFB	Lysosomal Enzymes (fibroblasts)	8	
NCSF	Neurotransmitters in CSF	8	
PTU	Pterins in Urine	9	
2.2.1. H	ybrid EQA Schemes' summary	10	
2.3. Qualita	tive Schemes	11	
ACDB	Acylcarnitines in dried blood spots	11	
AAI	Amino Acids Interpretation	11	
CDG	Congenital Disorders of Glycosylation (plasma/serum)	12	
DPT	Diagnostic Proficiency Testing (urine)	12	
QLOU	Qualitative Organic Acids (urine)	12	
UMPS	Urine Mucopolysaccharides	13	
2.3.1. Q	ualitative EQA Schemes' summary	14	
3. 2025 Calendar	(provisional)	15	
4. 2025 Price Lis	4. 2025 Price List		
5. Participation C	Guide	17	
6. Terms and Conditions of EQA Scheme Participation			

Version Date	Am	endments
16 th September 2024	•	2025 EQA Catalogue published
10 th December 2024	•	Page 7: Updated quantitative EQA schemes' summary table with addition of gentamicin to SAS samples
19th February 2025	•	Page 4: PPU information – Orotidine removed from list of analytes included in the scheme

1. Introduction

ERNDIM is an independent not-for-profit foundation which has been providing External Quality Assurance (EQA) schemes in the field of inborn errors of metabolism since 1994. While originally a European organisation we now have over 410 participants from over 60 countries, with approximately 40% of our participants coming from outside of Europe in 2024.

In 2025 we will be operating 17 EQA schemes which are developed & monitored by a Scientific Advisory Board comprising 22 leading scientists from 10 countries. You can find full details of the EQA schemes in section 2 (pages 4 to 14) and details of how to register to participate in the 2025 schemes in section 5 (pages 17 to 22).

The Participants' Guide on pages 17 to 22 includes information on all aspects of EQA scheme participation, including how to register, the use of EQA data in publications and how to pay your invoices. If you need further information for any of the items mentioned in the Participants' Guide please contact <u>admin@erndim.org</u>.

The terms and conditions of EQA Scheme Participation for Participating Centres can be found on pages 23 to 24. Please make sure that you read and understand these. When the primary contact for your centre logs into the ERNDIM Registration Website for the first time, after registration for the 2025 EQA schemes has opened, they will need to accept these terms and conditions before they will be able to submit their EQA order. If you have any questions about the terms and conditions, please contact admin@erndim.org.

2. EQA Schemes

2.1. Quantitative EQA Schemes

The main purpose of the quantitative schemes is to evaluate the ability of the participating laboratories to quantitatively analyse the concentrations of the analytes included in each scheme.

Details of the analytes included in each Quantitative scheme are below and full details of the scheme design (type and number of samples, subcontracted activities etc.) are given in section 2.1.1 on page 7.

Cluster Labs

Each participating laboratory must produce its own results and cannot send samples to a subcontracted or cluster laboratory. The use of cluster laboratories is therefore <u>not</u> allowed in any of the Quantitative schemes.

Acylcarnitines in serum⁺

- Aim: Comparison of Acylcarnitines analysis in a lab with respect to median and target values
- Status: Operating as a separate full EQA scheme since 2017; some acylcarnitines were previously included in the Special Assays in serum scheme
 - Analytes (2025):3-OH- Butyrylcarnitine (C4-OH)
3-OH-Isovalerylcarnitine (C5-OH)
3-OH- Palmitoylcarnitine (C16-OH)
3-OH-Stearoylcarnitine (C18-OH)
Acetylcarnitine (C2)
Butyrylcarnitine (C4)
Cis-5-Tetradecenoylcarnitine (C14:1)
Decanoylcarnitine (C10)
Dodecanoylcarnitine (C10)
Free Carnitine (C0)
Glutarylcarnitine (C5-DC)Scientific Advisor:Dr Pedro Ruiz-Sala, admin@erndim.org

Hexanoylcarnitine (C6) Isovalerylcarnitine (C5) Malonylcarnitine (C3-DC) Methylmalonylcarnitine (C4-DC) Octanoylcarnitine (C8) Oleoylcarnitine (C18:1) Palmitoylcarnitine (C16) Propionylcarnitine (C3) Stearoylcarnitine (C18) Tiglylcarnitine (C5:1) Total Carnitine

Scheme Organiser: MCA*

Purines and Pyrimidines (urine)⁺

Aim: Comparison of Purine and Pyrimidine analysis in a lab with respect to median and target values


Status: Full EQA scheme since 2000	
------------------------------------	--

Analytes (2025):	5-OH Methyluracil	Deoxy-guanosine	Pseudo-uridine
	3-Ureidoisobutyric acid	Deoxy-inosine	Succinyl adenosine
	3-Ureidopropionic acid	Deoxy-uridine	Thymidine
	Adenine	Dihydro-thymine	Thymine
	Adenosine	Dihydro-uracil	Uracil
	AICAriboside	Guanosine	Uric acid [‡]
	Creatinine (mmol/L) [‡]	Hypoxanthine	Uridine
	Cytidine	Inosine	Xanthine
	Deoxy-adenosine	Orotic acid	

[‡] Analytes marked with [‡] are present in the matrix so results can be recorded for comparison between labs <u>BUT</u> the concentrations do not vary, and they are not included in the Individual Online Annual Reports or Certificates of participation

Scientific Advisor: Dr Jörgen Bierau, <u>admin@erndim.org</u> Scheme Organiser: MCA⁺

⁺ Full details of the scheme design for each of the Quantitative schemes are given in section 2.1.1 on page 7.



Scheme Code: ACS

Scheme Code: PPU

Quantitative Amino Acids (serum)⁺

Aim: Comparison of Amino Acid analysis in a lab with respect to median and target values

Status: Full EQA scheme since 1993

Analytes ¹ (2025):	2-Aminobutyric acid	Cystine	Lysine	Taurine
	Alanine	Glutamic acid	Methionine	Threonine
	Allo-isoleucine	Glutamine	Ornithine	Tryptophan
	Arginine	Glycine	Phenylalanine	Tyrosine
	Argininosuccinic acid	Histidine	Proline	Valine
	Asparagine	Hydroxyproline	Sarcosine	
	Aspartic acid	Isoleucine	Serine	
	Citrulline	Leucine	Sulfocysteine	
Scientific Advisor:	Dr Rachel Carling, adm	nin@erndim.org		
Scheme Organiser:	MCA ⁺			

-

Quantitative Organic Acids (urine)†

Aim: Comparison of Organic Acid analysis in a lab with respect to median and target values

Status: Full EQA scheme since 1993 Analytes (2025): 2-Methylcitric acid Adipic acid Methylmalonic acid Creatinine (mmol/L) # 2-OH-Glutaric acid Mevalonic acid 3-Methylglutaconic acid Ethylmalonic acid N-acetylaspartic acid Fumaric acid Pyroglutamic acid 3-Methylglutaric acid 3-OH-3-Methylglutaric acid Glutaric acid Sebacic acid 3-OH-Butyric acid Hexanoylglycine Suberic acid 3-OH-Glutaric acid Isovalerylglycine Suberylglycine 3-OH-Isovaleric acid Keto-glutaric acid Tiglylglycine Vanillactic acid 3-OH-Propionic acid Malic acid 4-OH-Butyric acid Malonic acid

[‡] Analytes marked with [‡] are present in the matrix so results can be recorded for comparison between labs <u>BUT</u> the concentrations do not vary, and they are not included in the Individual Online Annual Reports or Certificates of participation

Scientific Advisor: Mme Clothilde Roux, admin@erndim.org

Scheme Organiser: MCA⁺

Special Assays in dried blood spots⁺

Aim: To educate and assess the ability of laboratories to analyse analyte levels in dried blood spots (DBS)

Status: Full EQA scheme since 2019

 Analytes (2025):
 Allo isoleucine
 Methionine

 Isoleucine
 NTBC (nitisone)

 Leucine
 Phenylalanine

 L-Homocysteine
 Succinylacetone

 Scientific Advisor:
 Dr Rachel Carling, admin@erndim.org

Scheme Organiser: MCA⁺

Scheme Code: SADB

Tyrosine Valine C0 free carnitine



Scheme Code: QTOU

ERNDIM

Special Assays in Serum⁺

- Aim: Comparison of outcome in heterogeneous group of lab-assays, relevant to the diagnosis of inborn errors of metabolism, in respect to median and target values. In addition, recovery of added analyte, precision, and analytical linearity are tested
- Status: Full EQA scheme since 1993

Analytes (2025): 3 OH Butyrate

7-Dehydrocholesterol 7-Ketocholesterol Biotinidase[‡] C22:0 Behenic acid C24:0 Lignoceric acid C26:0 Cerotic acid C26:0 LPC **Carnitine Free** Cholestane-3 β ,5 α ,6 β -triol

Cholestanol Cholesterol[‡] Coenzyme Q10 Creatine Galactose Glucosylsphingosine Guanidineacetic acid Homocysteine Lactic acid L-Pipecolic acid

Lyso-Gb3 Lysosphingomyeline Methylmalonic acid NEFA[‡] Phytanic acid Pristanic acid Pyruvic acid Succinylacetone

Scheme Code: SAU

[‡] Analytes marked with [‡] are present in the matrix so results can be recorded for comparison between labs BUT the concentrations do not vary, and they are not included in the Individual Online Annual Reports or Certificates of participation

Scientific Advisor: Dr Rafael Artuch, admin@erndim.org

Scheme Organiser: MCA⁺

Special Assays in Urine⁺

Aim: Comparison of outcome of a heterogeneous group of lab-assays, relevant to the diagnosis of inborn errors of metabolism, in respect to median and target values. In addition, recovery of added analyte, precision and analytical linearity are tested

Status: Full EQA scheme since 1993

Analytes (2025): 4-OH-Glutamic acid

5-Aminolevulinic acid 5-OH-Indolacetic acid **Carnitine Free** Creatine Creatinine D,L-Glyceric acid Galactitol

Glycolic Acid Guanidinoacetate Homocitrulline Homogentisic acid Homovanillic acid (HVA) Lactic acid L-Cystine

L-Pipecolic acid Orotic acid Oxalic acid Sialic acid Succinylacetone Sulfocysteine

Mucopolysaccharides (Chondroitin sulfate)

Scientific Advisor: Dr Rafael Artuch, admin@erndim.org Scheme Organiser: MCA⁺

Special Assays Combined

If you wish to order both the Special Assays in Serum and Special Assays in Urine scheme please select 'Special Assays Combined (serum + urine)' when submitting your order on the registration website and a discount for ordering both schemes will be applied to your order (see the EQA scheme price list on page 16).

⁺ Full details of the scheme design for each of the Quantitative schemes are given in section 2.1.1 on page 7.

Scheme Code: SAC

ERNDIM /

Scheme Code: SAS

2.1.1. Quantitative EQA Schemes' summary

Full detail of the analytes included in each scheme can be found on pages 4 to 6. For the provisional 2025 scheme calendar, see Section 3 on page 15.

	ACS	PPU	QTAS	QTOU	SADB	SAS	SAU
Detailed scheme information on page:	p4	p4	p5	p5	p5	p6	p6
General							
Eligibility Requirements:	Participa	nts must p	roduce the		ts and cannot send ter) laboratory	samples to	a sub-contracted
Use of cluster labs allowed?				,	Ňo		
Educational participation allowed? *					Yes		
No. of registrations (2024):	129	52	276	136	121	277	212
Geographic area:				W	orldwide		
Sample volume/vial	0.5ml	2.5ml	1ml	5ml	75 µl initial blood volume	5ml	5ml
Matrix of human origin, spiked with commercially available analytes					Yes		
Matrix:							
Dried blood spots					Yes		
Lyophilised plasma/serum	Yes		Yes			Yes	
Lyophilised urine		Yes		Yes			Yes
Sample treated with gentamicin	micin No Yes			No			
Scheme Design							
Sample design/selection:	Scientific Advisor for each scheme						
Sample manufacture subcontracted to:	MCA						
Sample aliquoting subcontracted to:					MCA		
Sample Dispatch subcontracted to:					dispatch per year		
Country samples will be dispatched from:				Ne	therlands		
No of samples/year:					8		
Results Submissions							
No of submission deadlines/year:					8		
Submission of results:			C	nline (ERN	DIM-MCA website)		
Scoring of results:							
Analysis scored	Yes						
Reports:							
Interim Reports							
Published 14 days after each	, , , , , , , , , , , , , , , , , , ,						
submission deadline	Yes						
Individual Lab Annual Reports							
Published 14 days after the last							
submission deadline	line						
Scheme Annual Reports (AR)	published in Jan-Mar of the following year						
Full anonymised scheme results included in AR	No						

* = For more information on Educational Participation see page 17 in the Participants' Guide section of this catalogue.

2.2. Hybrid EQA Schemes

The main purposes of the hybrid schemes are to evaluate the ability of the participating laboratories to: 1) quantitatively analyse the concentrations of the analytes included in each scheme; <u>and</u> 2) establish or exclude a specific diagnosis of an inherited metabolic disease (IMD).

Details of the analytes included in each Hybrid scheme are below and full details of the scheme design (type and number of samples, subcontracted activities etc.) are given in section 2.2.1 on page 10.

Cluster Labs

Each participating laboratory must produce its own results and cannot send samples to a subcontracted or cluster laboratory. The use of cluster laboratories is therefore <u>not</u> allowed in any of the Hybrid schemes.

Cystine in White Blood Cells^{††} Aim: Comparison of analysis of Cystine in White Blood Cells (WBC)

Status: Full EQA scheme since 2005

No. of samples/year:	8 pairs of protein and WBC supernatants
Volume/sample:	Lyophilised pellet and 250µl supernatant equivalent to extracts from 5 ml whole blood samples
Sample matrix:	Lyophilised pellet from protein standard, WBC supernatants are liquid
Analytes (2025):	Cystine (nmol/aliquot) (250 µL SNT sample) Protein (mg/pellet) (PP sample) Cystine (nmol 1/2 cys/mg protein, calculated as if isolated from 5 mL blood sample)
Scientific Advisor:	Dr Daniel Herrera, <u>admin@erndim.org</u>
Scheme Organiser:	MCA ⁺⁺

Lysosomal Enzymes (fibroblasts)⁺⁺

Aim: Testing of reproducibility and ability to detect enzyme deficiencies in lysosomal storage disorders

Status: Full EQA scheme since 2011

Expected Enzymes (2025): Acetyl-CoA-glucosamine acetyltransferase Alpha-galactosidase Alpha-glucosidase Arylsulphatase A Arylsulphatase B Beta-galactosidase

Beta-glucosidase Beta-mannosidase Iduronate sulphatase Tripeptidyl peptidase 1 Protein

Please note, as these are clinical samples, enzymes may vary depending on the availability of samples

Scientific Advisor: Dr Ed Jacobs, admin@erndim.org

Scheme Organiser: MCA⁺⁺

Neurotransmitters in cerebrospinal fluid (CSF)^{*tt*}

Aim: To educate and assess the ability of laboratories to diagnose inborn errors of neurotransmitter metabolism

Status: Full EQA scheme since 2016

 Analytes (2025):
 3-methyl dopa (3-MD)

 5-OH-Indolacetic acid (5-HIAA)

 5-OH-Tryptophan (5-HTTP)

 5-methyltetrahydrofolate (5-MTHF)

 Scientific Advisor:
 Dr Simon Pope, admin@erndim.org

 Scheme Organiser:
 MCA**

Biopterin Homovanillic acid (HVA) HVA:5-HIAA ratio Neopterin

⁺⁺ Full details of the scheme design for each of the Hybrid schemes are given in section 2.2.1 on page 10.

Scheme Code: NCSF

Scheme Code: LEFB

Scheme Code: CWBC

Pterins in Urine ⁺⁺	Scheme Code: PTU
Aim: To educate and assess the ability of laboratorie metabolism	es to diagnose inborn errors of tetrahydrobiopterin (BH ₄)
Status: Full EQA scheme since 2017	
Analytes (2025): Creatinine (mmol/L) Biopterin (μmol/L & mmol/m	Neopterin (μmol/L & mmol/mol Creat) ol Creat) Primapterin (μmol/L & mmol/mol Creat)
Scientific Advisor: Dr Alessio Cremonesi, adm	in@erndim.org
Scheme Organiser: MCA ⁺⁺	

^{*tt*} Full details of the scheme design for each of the Hybrid schemes are given in section 2.2.1 on page 10.

ERNDIM

2.2.1. Hybrid EQA Schemes' summary

Full detail of the analytes included in each scheme can be found on pages 8 to 9. For the provisional 2025 scheme calendar, see Section 3 on page 15.

	CWE	3C	LEFB	NCSF	PTU
Detailed scheme information on page:	p8	3	p8	p8	p9
General					
Eligibility Requirements:	Participants			Ilts and cannot s ster) laboratory	end samples to a
Use of cluster labs allowed?			No		
Educational participation allowed? *			Yes		[
No. of registrations (2024):	42	-	71	38	36
Geographic area:			Worldwid	le	
EQA Samples		1	T	r	r
Sample volume/vial	Lyophilised protein pellet	250µl supernatant	0.5 mg lyophilised protein	1ml	1ml
Sample type			1		1
Artificial/human matrix				Yes	
spiked with commercially available analytes					
Clinical samples		1	Yes		
Matrix of human origin, with commercially available		Yes			Yes
analytes Matrix:					
Lyophilised cerebrospinal fluid				Yes	
Lyophilised fibroblasts			Yes	163	
Lyophilised protein	Commercial protein standard (human origin)		100		
Lyophilised urine					Yes
White blood cells		Yes			
Scheme Design		·	·	<u>.</u>	·
Sample design/selection:		Scienti	fic Advisor for	each scheme	
Sample manufacture subcontracted to:	MC		CHU Lyon & MCA	MCA	University Children's Hospital, Zurich & MCA
Sample aliquoting subcontracted to:			MCA		
Sample Dispatch subcontracted to:		MC	A: one dispate		
Country samples will be dispatched from:			Netherlan	r	
No of samples/year:	8 ³	; 	6	8	8
Results Submissions			I		
No of submission deadlines/year:	8		2	8	8
Submission of results:		onlin	e (ERNDIM-M	CA website)	
Quantitative results submission is mandatory			Yes		
Interpretation results submission is mandatory			Yes		
Scoring of results:					
Analysis scored			Yes		
Diagnoses Scored			Yes		
Reports:					
Interim Reports			04		
Published after each submission deadline (no. days)			21		
Individual Lab Annual Reports Published after the submission deadline	lo	0		Jan	Jan
Scheme Annual Reports (AR)			1		
Full anonymised scheme results included in AR	_		Yes	-	-
			100		I

 3 = 8 pairs of protein and WBC supernatants, see page 8.

* = For more information on Educational Participation see page 17 in the Participants' Guide section of this catalogue.

2.3. Qualitative EQA Schemes

The main purpose of the Qualitative schemes is to evaluate the ability of the laboratory to establish or exclude a specific diagnosis of an inherited metabolic disease (IMD). Participants are expected to obtain correct analytical results, to recognize the characteristic diagnostic patterns, to make a diagnostic conclusion and to suggest additional test(s) necessary to confirm the diagnosis. These schemes use clinical samples as the EQA materials.

Details of the analyte groups included in each Qualitative scheme are below and full details of the scheme design (number of samples, submission deadlines, subcontracted activities etc.) are given in section 2.3.1 on page 14.

When schemes are organised by more than one centre, participants will be assigned to a centre by the Administration Office.

Sample Donations

For some Qualitative schemes, a 20% discount on the scheme price is available to participants that donated a sample that was used as an EQA material in the <u>previous</u> scheme year. The Admin Office will automatically add this discount to the invoices for qualifying laboratories after the order has been submitted. For more details, please contact <u>admin@erndim.org</u>.

Cluster Labs

For all Qualitative schemes, <u>except</u> the DPT scheme, each participating laboratory must produce its own results and cannot send samples to a subcontracted laboratory. The use of cluster laboratories is therefore <u>not</u> allowed in any of the Qualitative schemes, except for the DPT scheme, and <u>participating laboratories must carry out</u> both the analysis and interpretation of the EQA samples.

Acylcarnitines in drie	d blood spots ⁺⁺⁺	Scheme Code: ACDB
Aim: To educate and as whole blood acylc	ssess the ability of laboratories to detect inherited disc arnitine profiles	orders resulting in recognisable
	003 (London only). In 2010 and 2017 additional centre added due to increasing participant numbers. In 2018	
Eligibility Requirements:	Participating laboratories must carry out both the an EQA samples. The use of cluster laboratories is r	
Analytes:	Dependent upon disorder	
Scientific Advisors:	Heidelberg: Dr Joachim Janda, <u>admin@erndim.org</u> London: Mrs Erin Emmett, <u>admin@erndim.org</u> Rome: Dr Cristiano Rizzo, <u>admin@erndim.org</u>	
Scheme Organisers:	CSCQ ^{†††}	

Amino Acids Interpre	tation ^{***}	Scheme Code: AAI
	ssess the ability of laboratories to detect inherit acids in plasma and other specimens	ed disorders resulting in recognisable
Status: Running as a full E & 2021-2022)	EQA scheme for the first time in 2023 (previous	sly ran as a pilot scheme in 2017-2019
Eligibility Requirements:	Participating laboratories must carry out the interpr of cluster laboratories is not allowed.	retation of the EQA sample data. The use
	The number of participants for 2025 is limited, with	previous participants taking priority.
Samples:	Clinical information and <u>quantitative values</u> fo CSF (with reference ranges) are circulated.	r amino acids in plasma, urine and
	Note: samples are data only, no physical s scheme	amples are circulated for this
Analytes:	Amino acids in plasma (<u>data only</u>)	
Scientific Advisor:	Dr Sabine Scholl-Bürgi, <u>admin@erndim.org</u>	
Scheme Organisers:	ERNDIM, admin@erndim.org	

⁺⁺⁺ Full details of the scheme design for each of the Qualitative schemes are given in section 2.3.1 on page 14.

ERNDIM

Congenital Disorders of Glycosylation (plasma/serum)*** Scheme Code: CDG Aim: Qualitative interpretation of sialotransferrin profiles in the screening for Congenital Disorders of Glycosylation (CDG) Status: Full EQA scheme since 2010 Eligibility Requirements: Participating laboratories must carry out both the analysis and interpretation of the EQA samples. The use of cluster laboratories is not allowed. Volume/sample: 25 microlitres (If you require extra sample volume in order to carry out the analysis, a maximum of 2 extra sample sets per participant can be purchased at a discounted price, however please note that availability is limited due to the nature of the EQA materials. Please contact admin@erndim.org if you would like further details.) Analytes: Sialotransferrin isoforms Scientific Advisor: Dr Dulce Quelhas, admin@erndim.org Scheme Organiser: MCA and CSCQ***

Diagnostic Proficiency Testing (urine) ***

Scheme Code: DPT

- Aim: To assess test selection, analysis, interpretation and advice in the performance of tests related to the detection of inherited metabolic disorders
- Status: Operated since 1990 (Netherlands only). In 1998 a further 3 organising centres were added (Czech Republic, France and UK) and in 2006 a fifth centre (Switzerland) was added as part of the EuroGentest project. [Each organising centre focuses on a separate geographic area]

Eligibility Requirements:	Any urine sample can be sent that a laboratory operating to expected standards would be able to diagnose, but participants should be able to perform this core panel of tests: amino acids, organic acids, oligosaccharides, mucopolysaccharides, purines & pyrimidines. If your laboratory does not offer this core panel of tests it may not be possible to obtain satisfactory performance and we strongly recommend that you do not register for the DPT scheme. The use of cluster labs, for instance for purines & pyrimidines, is acceptable but the participant lab is responsible for the results submitted.
Analytes:	Dependent upon disorder
Scientific Advisors:	Czech Republic: Mr Petr Chrastina, admin@erndim.org
	France: Dr Christine Vianey-Saban, admin@erndim.org
	Netherlands: Dr George Ruijter, admin@erndim.org
	Switzerland: Dr Déborah Mathis, admin@erndim.org
	UK: Mrs Joanne Croft, admin@erndim.org

Scheme Organiser: CSCQ⁺⁺⁺

Qualitative Organic Acids (urine)^{*ttt*}

Scheme Code: QLOU

- Aim: To educate and assess the ability of laboratories to detect inherited disorders resulting in recognisable patterns of organic acid excretion
- Status: Operated since 1992 (Sheffield only), with additional centres in Heidelberg and Barcelona added in 2002 and 2018, respectively, due to increased participant numbers.

Eligibility Requirements: Participating laboratories must carry out both the analysis **and** interpretation of the EQA samples. **The use of cluster laboratories is not allowed.**

- Analytes:
 Dependent upon disorder

 Scientific Advisors:
 Barcelona: Dr Judit Garcia-Villoria, admin@erndim.org
- Heidelberg: Dr Joachim Janda, <u>admin@erndim.org</u> Sheffield: Mrs Camilla Scott, <u>admin@erndim.org</u> Scheme Organiser: CSCQ^{##}

^{*ttt*} Full details of the scheme design for each of the Qualitative schemes are given in section 2.3.1 on page 14.

Urine Mucopolysaccharides ***Scheme Code: UMPSAim: To educate and assess the ability of laboratories to detect mucopolysaccharidosesStatus: Full EQA scheme since 2012Eligibility Requirements:Participating laboratories must carry out both the analysis and interpretation of the EQA samples. The use of cluster laboratories is not allowed.Analytes:Quantitative (related to creatinine) and qualitative analysis of mucopolysaccharides with interpretation of results obtainedScientific Advisor:Dr Berthil Prinsen, admin@erndim.org

Scheme Organiser: MCA and CSCQ⁺⁺⁺

⁺⁺⁺ Full details of the scheme design for each of the Qualitative schemes are given in section 2.3.1 on page 14.



2.3.1. Qualitative EQA Schemes' Design summary

Full detail of the analyte groups included in each scheme can be found on pages 11 to 13. For the provisional 2025 scheme calendar, see Section 3 on page 15.

	DPT	AAI	ACDB	CDG	QLOU	UMPS				
Detailed scheme information on page:	p12	p11	p11	p12	p12	p13				
General	p	P	P			P.0				
	No. Vez									
Method Orientated scheme?	No		Yes							
Eligibility Requirements:	See DPT information on p12	Participants must produce their own results and cannot send samples/cases to a sub-contracted (or cluster) laboratory								
Use of cluster labs allowed?	Yes	No								
Educational participation allowed? *	١	No		Yes						
No of organising centres:	5	1	3	1	3	1				
No. of registrations (2024):	96 (17-21 per centre)	143	134 (44-45 per centre)	95	235 (77-80 per centre)	95				
Geographic area:			Worl	dwide						
EQA Samples										
Sample volume/vial:	5-10ml	n/a	30-50µl	25 µl⁴	2-3 ml/vial	5ml				
Sample type	Clinical Data from									
Matrix:										
Data from plasma, urine & CSF samples		Yes								
Dried Blood Spots on S&S903 filter paper			Yes							
Heat treated urine	Yes				Yes					
Lyophilised plasma/serum				Yes						
Lyophilised urine						Yes				
Scheme Design		-	-	-						
Sample design/selection	Scientific Advisors (SA) for each scheme									
Sample aliquoting subcontracted to:	CSCQ	n/a	SA	MCA	CSCQ	MCA				
Sample Dispatch subcontracted to:		Π/α	-	-						
(one dispatch per year)	CSCQ	n/a	CSCQ	MCA	CSCQ	MCA				
Country samples will be dispatched from:	Switzerland	n/a	Switzerland	Netherlands	Switzerland	Netherlands				
No of samples/year	6									
· · · ·			,	0						
Results Submissions				0						
No of submission deadlines/year Submission of results	Online (ERNDIM- CSCQ website)	Online (ERNDIM form)	2 Online (ERNDIM-CSCQ website)							
Scoring of results:										
Analysis of physical samples	Yes	No	No Yes							
Analysis of data samples only	No	Yes			lo					
Interpretation, including diagnoses	Yes									
Reports:										
Interim Reports										
Published 8-10 weeks after the submission deadline	Yes	Yes	Yes	No	Yes	Yes				
Diagnoses circulated by email 2-3 weeks after										
submission deadline										
Individual Lab Annual Reports										
Published following moderation of scoring at	t									
the Autumn Scientific Advisory Board meeting										
Scheme Annual Reports (AR)	Published in Jan-Mar of the following year									
Full anonymised scheme results included in AR										
i un anonymiseu scheme results included III AR	163									

⁴ = see CDG scheme information on page 12

* = For more information on Educational Participation see page 17 in the Participants' Guide section of this catalogue.

3. 2025 Calendar (provisional)

Please note the schedules in this calendar are provisional only. Please check the EQA calendar on the EQA tab of the ERNDIM website (<u>www.erndim.org</u>), which, from the end of January 2025, will be updated with confirmed dates as they become available.

		Quantitative Schemes						Hybrid Schemes				Qualitative Schemes						
Year	Month	ACS	PPU	QTAS	QTOU	SADB	SAS	SAU	CWBC	LEFB	NCSF	PTU	ACDB	AAI	CDG	DPT	QLOU	UMPS
	Sep	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
4	Oct	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
-1	Nov	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
	Dec																	
Scheme Year	Jan																	
	Feb	D	D	D	D	D	D	D	D	D	D	D	D		D	D	D	D
	Mar	S	S	S	S	S	S	S	S		S	S						
	Apr	S	S	S	S	S	S	S	S		S	S	S			S		
	Мау	S	S	S	S	S	S	S	S	S	S	S		D S	S		S	S
	Jun	S	S	S	S	S	S	S	S		S	S	S			S		
	Jul	S	S	S	S	S	S	S	S		S	S						
	Aug	S	S	S	S	S	S	S	S	S	S	S		D				
	Sep	S	S	S	S	S	S	S	S		S	S		S	S		S	S
	Oct	S	S	S	S	S	S	S	S		S	S						
	Nov																	
	Dec																	
	Jan	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL
+1	Feb	А	A	A	A	А	A	A	A	A	A	A	A	A	A	A	A	A
	Mar	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
	mai	С	С	С	С	С	С	С	С	С	C	C	С	C	C	C	С	С

R = Registration open

D = Sample Dispatch

S = Submission Deadline

PSL = Performance Support Letters sent

A = Appeals open

AR = EQA scheme Annual Reports published

C = Certificates of Participation published

4.2025 Price List

1 Carl	
10	

		2025 Prices			
EQA Schemes	Scheme Code	Euro	GB Pounds	US\$	
1. Quantitative Schemes					
Acylcarnitines in serum	ACS	413	373	487	
Purines and Pyrimidines (urine)	PPU	459	414	541	
Quantitative Amino Acids (serum)	QTAS	365	330	431	
Quantitative Organic Acids (urine)	QTOU	435	393	513	
Special Assays in dried blood spots	SADB	302	272	357	
Special Assays (serum)	SAS	237	214	280	
Special Assays (urine)	SAU	225	203	265	
Special Assays Combined (serum & urine)	SAC	413	373	487	
2. Hybrid Schemes					
Cystine in White Blood Cells	CWBC	453	409	534	
Lysosomal Enzymes (fibroblasts)	LEFB	780	704	920	
Neurotransmitters (CSF)	NCSF	455	411	537	
Pterins in Urine	PTU	441	398	520	
3. Qualitative Schemes					
Acylcarnitines (dried blood spots) *	ACDB	413	373	487	
Amino Acids Interpretation	AAI	165	140	169	
Congenital Disorders of Glycosylation (serum) *	CDG	423	381	498	
Diagnostic Proficiency Testing (urine) *	DPT	589	532	695	
Qualitative Organic Acids (urine) *	QLOU	444	401	524	
Urine Mucopolysaccharides *	UMPS	396	357	467	
Mailing fee per scheme for	31.50	27	37		

Please note:

- VAT at 20% will be added to invoices for all UK laboratories.
- The mailing fee <u>per scheme</u> will added to the invoices for ALL laboratories unless the laboratory provides their own courier account number to be used for sample dispatch.
- * For these schemes a 20% discount on the scheme price is available to participants that donated a sample that was used as an EQA material in the <u>previous</u> scheme year. The Admin Office will automatically add this discount to the invoices for qualifying laboratories after the order has been submitted. For more details please contact <u>admin@erndim.org</u>.

5. Participation Guide

5.1. Registering for EQA Schemes

Registration for the next year's EQA schemes opens in the September of the previous year and is only available for a defined period. For the 2025 EQA schemes, registration will be open from **mid September to early November 2024** (see <u>www.erndim.org</u> for the exact dates). In some circumstances late registration may be possible but



will be dependent upon sample availability and the agreement of the relevant Scientific Advisor.

Details of how to access the ERNDIM Registration Website (<u>www.eqa.erndim.org</u>) are sent to all existing EQA participants in September of each year and are available from the ERNDIM Administration office upon request.

All EQA scheme orders **must** be submitted using the ERNDIM Registration Website.

If your laboratory already participates in an ERNDIM EQA scheme the Registration Website will show all the contact and address information which is held by ERNDIM for your laboratory.

It is the responsibility of the person listed as the primary laboratory contact to provide the ERNDIM Administration office with valid, up to date contact and address details:

1. The primary laboratory contact should check that all the information is correct and update it where necessary. The information should include:

- Email addresses for a primary and secondary contact persons*
- Email address for named Head of Laboratory or Quality Manager*. If a laboratory does not supply the contact details for the Head of laboratory or Quality Manager, ERNDIM reserves the right to withhold the laboratory's Certificate of Participation until such time as the contact details are supplied (see section 5.14.).

* these contact details must be for 3 different people

- A postal address for the participating laboratory.
- A delivery address for EQA materials.
- An invoice address and named invoice contact with email address.

2. Select the EQA schemes that you wish to participate in during the next year.

3. Add a purchase order number to the registration form, if your hospital or laboratory procedures require it to be on the invoice, and then

4. Submit your order.

Any subsequent change in contact persons or

address details **must** be sent to the ERNDIM Administration office (<u>admin@erndim.org</u>) as soon as possible.

New participants should email the ERNDIM Administration office to request access to the ERNDIM Registration Website.

If you have any problems with registering for the EQA schemes please contact <u>admin@erndim.org</u>.

5.2. Terms & Conditions of EQA scheme registration

All participant laboratories must accept the terms and conditions on the ERNDIM Registration Website before an EQA scheme order can be submitted. The terms and conditions are on page 23 of this catalogue and can also be viewed on the ERNDIM Registration Website.

5.3. Confidentiality

Laboratory information is confidential and is only shared with the ERNDIM Administration office, the Scientific Advisors and the scheme organisers. All participating laboratories are given a unique ERNDIM reference number which should be used in all correspondence with ERNDIM.

The fact that your laboratory participates in ERNDIM schemes is not confidential, however, the raw data and performance scores are confidential and will only be shared within ERNDIM for the purpose of evaluating your laboratory's performance (which may include sharing information between the ERNDIM schemes that you subscribe to), unless ERNDIM is required to disclose performance data by a relevant government agency.

Please see the terms and conditions on page 23 for details of our confidentiality policy for laboratory information; and the <u>ERNDIM Privacy Policy</u> on



<u>www.erndim.org</u>, for details of the personal information we collect and store, and your rights regarding that data.

5.4. Use of ERNDIM EQA data in publications

Data derived from the use or analysis of ERNDIM EQA materials <u>must not</u> be used in written publications or oral presentations unless the explicit prior consent of ERNDIM has been granted.

If you wish to use data derived from ERNDIM EQA materials you <u>must</u> contact the Administration Office to obtain permission <u>before</u> publication.

For EQA materials based on real clinical samples, permission to use the data will be dependent on the appropriate consent being in place.

If permission to use the data is granted, ERNDIM must be acknowledged in the publication or presentation using a standard acknowledgement sentence which will be provided by the ERNDIM Administration Office, and a copy of the publication, with full reference/citation information, should be sent to the ERNDIM Administration Office.

5.5. EQA participation fees

The price list for the 2025 EQA schemes can be found on page 16 of this catalogue.

A mailing charge per scheme will be added to the EQA order unless the you provide the details of a courier account to be used for the sample dispatch.

VAT at 20% will be added to invoices for all UK laboratories.

5.6. Laboratory Support Grants

A limited number of Laboratory Support Grants are available to provide financial support for laboratories which due to financial restrictions find it difficult to fund participation in one or more of the ERNDIM EQA schemes.

Laboratory Support Grants are awarded annually by the ERNDIM Board on a competitive basis with the aim of allowing laboratories to extend their repertoire of EQA scheme participation.

If you would like to apply for a Laboratory Support Grant please complete and return the application form, which can be found on the ERNDIM website under EQA Schemes/Laboratory Support Grants.



Applications for support during the 2025 scheme year must be received by the Administration Office during the registration period.

5.7. Educational participation

Educational Participation is open to laboratories that are participating in an EQA scheme to help with setting up a new test but are not yet offering a clinical service.

Participants that select Educational Participation when registering for an EQA scheme MUST send a completed and signed Educational Declaration form to the ERNDIM Administration office.

Educational Participation in a scheme is not confirmed until the Administration office confirms that your application has been accepted. Please note the number of Educational Participants per scheme is limited and Educational Participation is not available for the AAI or DPT scheme.

The Educational Participation Declaration forms can be found on the ERNDIM Registration website (<u>www.eqa.erndim.org</u>) under Participant Information. There is one form for the qualitative schemes and separate forms for each of the quantitative and hybrid schemes.

For each EQA scheme in which you wish to be an Educational Participant, a separate Declaration form needs to be completed, and sent to admin@erndim.org,

5.8. Sample Donation



Several of the ERNDIM EQA schemes use real clinical samples as the EQA materials however, it is becoming increasingly difficult to source suitable clinical samples. Details of the types of samples that would be useful to ERNDIM can be found on the <u>EQA schemes tab of the ERNDIM website.</u> If you think you would be able to donate a clinical sample (with the appropriate patient consent) to ERNDIM please contact <u>admin@erndim.org</u>.

5.8.1. Scheme Discounts

If a sample donated by your laboratory is used as an EQA material in one of the Qualitative EQA schemes, you will qualify for a 20% discount on the cost of that specific scheme when you register for the following scheme year. The Administration office automatically applies this discount to orders from qualifying laboratories once the order has been submitted.

The maximum discount that can usually be applied is 20% per laboratory per scheme regardless of how many donated samples are used in a scheme year.

5.9. EQA scheme timetables

A provisional EQA calendar is on page 15. From the end of January in each year, the EQA calendar will also be available to download on the <u>ERNDIM</u> <u>website under EQA schemes</u>. Information is added to the calendar as it becomes available.

5.10. Sample Dispatches

Sample dispatch dates will be given on the ERNDIM website by the end of January, but are usually in early February. Additionally, all participants will be sent emails with dispatch information 1-2 weeks before sample dispatch.

5.10.1. Replacement Samples

If you do not receive the EQA sample parcel within the time specified in the sample dispatch alert email please contact the ERNDIM Administration Office (admin@erndim.org).



5.11. Analysis and Reporting

You will receive instructions on sample testing and reporting processes with the sample shipments. Scheme instructions will also be available to download from the ERNDIM Registration website (<u>www.eqa.erndim.org</u>) under Participant Information, or by contacting admin@erndim.org.

EQA samples must be treated in the same way as clinical samples.

Details of the submission deadlines for each scheme are given in the scheme instructions you will receive with the sample parcel and in the EQA calendar on the EQA schemes tab of the ERNDIM website (<u>www.erndim.org</u>). EQA scheme instructions can also be downloaded from the Registration Website (<u>www.eqa.erndim.org</u>) under Participant Information.

Reports and results will be released according to individual scheme timetables. Please note: Data derived from any EQA reports should not be used in any written publications or oral presentations unless the explicit prior consent of ERNDIM has been granted. See item 5.4 for details.

If a laboratory persistently does not submit results, or submits insufficient results for performance to be assessed this will be shown on the Certificate of Participation. ERNDIM also reserves the right to restrict the laboratory's participation in the EQA scheme(s) in future years.

5.11.1. Late results submission or amending submitted results

We strongly recommend that all submitted results are printed and checked <u>before</u> the relevant deadline. If you do miss a submission deadline or realise after the deadline that you need to amend an already submitted result, please contact admin@erndim.org as soon as possible.

However, please note that <u>extensions will only be</u> <u>allowed under **exceptional** circumstances</u> and no late/amended results can be accepted if the relevant consensus results or diagnoses have already been published.

5.12. Final Scheme Annual reports

For each EQA scheme an Annual report is published after the end of the scheme year. All the available EQA scheme Annual reports can be downloaded from the ERNDIM website under <u>Meeting and</u> <u>Reports</u>.

Please note: Data derived from EQA scheme annual reports should not be used in any written publications or oral presentations unless the explicit prior consent of ERNDIM has been granted. See item 5.4 for details.

5.13. Performance Assessment

Submitted results are evaluated according to ERNDIM policies and procedures, which are available upon request.

The number of points required for satisfactory performance in each EQA scheme is defined by the Scientific Advisor, ratified by the Scientific Advisory Board (SAB) and is reviewed annually.

Satisfactory performance in an EQA scheme is based solely on the laboratory's performance in that scheme year and does not guarantee future performance.

ERNDIM is not responsible for the performance of participating laboratories.

5.13.1. Critical Errors

For the Qualitative and Hybrid EQA schemes any errors which would be unacceptable to the majority of laboratories will be separately assessed as Critical Errors.

An absence of Critical Errors is required for satisfactory performance. Any laboratory that makes a Critical Error will be classed as a poor performer regardless of their overall score in the EQA scheme.

The critical errors for each scheme year will be proposed by the Scientific Advisors for the individual EQA schemes and will be ratified at the SAB Meeting held after the completion of the EQA scheme year.

Lists of the Critical Errors agreed for previous scheme years can be found on the ERNDIM website under <u>Meetings & Reports\Other Reports</u>.



5.13.2. Performance Support Letters

Laboratories that have unsatisfactory performance or fail to return sufficient results will be sent a Performance Support Letter by ERNDIM.

The aim of the performance support letter is to begin a dialogue between the Scientific Advisor and the participating laboratory in order to solve any particular analytical problems and to help the laboratory improve performance.

If a laboratory does not respond to the Performance Support Letter ERNDIM reserves the right to contact the Laboratory Head or Quality Manager.

Performance Support Letters will also be sent to the Laboratory Head or Quality Manager for cases of Global Poor Performance (poor performance in more than one EQA scheme in one year) and Persistent Poor Performance (poor performance in an EQA scheme for at least 2 out of 3 years during which the participant has submitted results).

In the rare instances that a lab is a Persistent Global Poor Performer (poor performance in more than one EQA scheme in at least 2 out of 3 participating years) ERNDIM reserves the right to contact the administration of the relevant institution.

5.14. Certificates of Participation

A certificate showing which EQA schemes you have registered for, participated in and your laboratory's performance in those schemes is issued after the end of the scheme year when all scheme results have been finalised.

ERNDIM reserves the right to withhold the certificate of participation in cases where:

- The relevant ERNDIM invoice has not been paid
- The Head of Laboratory or Quality Manager Contact has not been provided
- A laboratory has been found to be colluding, or is strongly suspected of colluding, with another laboratory (see section 5.15).

5.15. Collusion

Participants found to be colluding, or which are strongly suspected of colluding, with another laboratory in their scheme returns may have their



certificates of participation withheld and be excluded from participation in future schemes.

5.16. Appeals, Complaints & Feedback

Problems relating to EQA Schemes, including appeals and complaints from participating laboratories, should be referred directly to the ERNDIM Administration Office (admin@erndim.org).

5.16.1. Appeals

If you wish to appeal against the evaluation of your laboratory's performance in an EQA scheme a formal appeal must be submitted using the online appeals form (link included in the performance support letter), within 4 weeks of the date of the performance support letter.

Appeals against classification as a poor performer due to score are initially considered by the EQA scheme Scientific Advisor with any further appeals being considered by the ERNDIM Executive Committee.

Appeals against classification as a poor performer due to a critical error will be considered by the Executive Committee.

5.16.2. Complaints

If a complaint is received it will be logged along with the action taken. The office staff will attempt to



address the complaint as soon as possible. If the participant is not satisfied with the response then the matter will be brought to the Executive Committee at their next meeting and a response made in light of their advice.

5.16.3. Feedback to ERNDIM

Confidential communications about a scheme can be made to the Administration Office.

A participant survey is also conducted annually. The results of this survey are shared with the ERNDIM Management Committees and a survey report is uploaded to the ERNDIM website under <u>Meetings and Reports</u>.

5.17. Subcontracted Activities

Some activities such as the manufacture of materials, dispatch of samples and hosting and maintenance of websites are subcontracted but ERNDIM remains responsible for the oversight of subcontracted activities.

Details of the sub-contracted activities for each scheme are included in the scheme information in section 2 of this catalogue and are also available on the EQA schemes tab of the ERNDIM website (www.eqa.erndim.org).

5.18. Training Support Grants

As part of our aim to help improve standards in biochemical genetic testing ERNDIM offers a small number of Training Support Grants each year.

This grant is designed for trainees, in a permanent laboratory position, to gain experience and knowledge in a European ERNDIM approved laboratory in order to develop or introduce new methods to their own laboratory.

2025 EQA Schemes Catalogue & Participants' Guide (DOC2218)

Funds can be applied for to cover the travel and accommodation costs incurred by such visits and a maximum of 6 grants will be awarded each year, subject to the approval of the ERNDIM Executive Committee. Full application criteria are given in the application form which can be found on the ERNDIM website under <u>Training/Training Support Grants</u>.

5.19. Invoicing & Payment Information 5.19.1. Invoices

For participants that submit an EQA scheme order by the Registration deadline, invoices will be sent out in December and will be dated 1st January of the following year, as requested by a number of laboratories.

If your hospital or laboratory procedures require a purchase order number be included on the invoice,



this should be added to your order on the ERNDIM Registration Website.

If you receive a purchase order number from your finance department after the Registration period has closed, please send it to the Administration Office as soon as possible so it can be added to your invoice.

The invoice payment date will be stated on the invoice but for orders submitted within the Registration period, **invoice payments must be received by ERNDIM by 1**st **April in the scheme year**, unless an earlier date (due to late payment of a previous invoice) or later date (due to late registration) is specified.

The invoice of participants that submit a late registration request will be dated with the issued date and the payment date will be 1st April or 8 weeks from the issued date, whichever is later.

Invoices show:

- The EQA schemes chosen.
- The subscription fees for those schemes and associated mailing charges.
- Any discounts applied due to sample donation or awarded grants.
- Any balance brought forward from previous invoices.

Invoices will be sent by email only to the primary, secondary and invoice contacts for each

laboratory. It is the responsibility of the primary laboratory contact to ensure they provide a valid invoice address, invoice contact name and invoice email address.

The participant **must** check the information in the invoice. If all details are correct the invoice should be passed for payment to the appropriate finance department.

If any details on the invoice are not correct the ERNDIM Administration office (<u>admin@erndim.org</u>) should be notified by mid-December and a revised invoice will be issued.

It is the responsibility of the participant laboratory to ensure that the ERNDIM invoice is paid.

Late payment will incur penalties as specified below:

- Interest charges of 1.3% per month are applied to outstanding balances after the invoice payment date. When interest is added to the outstanding balance an updated invoice with a new version number will be sent to the participant.
- If there is still an outstanding invoice balance after the 1st July, in the next year the invoice payment date will be 31st January and the dispatch of samples to the laboratory in that year will be delayed until ALL outstanding invoices have been paid.
- If there is still an outstanding invoice balance after the 1st August, access to the EQA scheme results will be restricted until the invoice has been paid.
- If there is still an outstanding invoice balance after the 1st September, in the same year as the scheme participation, the laboratory will not be eligible to register for any ERNDIM EQA schemes until all outstanding invoices have been paid and a Certificate of Participation for the current year will not be issued.



5.19.2. Payment Information

ERNDIM accepts payments in Euro, GB pounds or US dollars and it is important that the correct bank account is used for payments in each currency. Payments which are made into the wrong bank account (for example a payment in Euros paid into the GB pounds account) can result in losses due to the bank exchange rate. Any losses which are a result of a participant making a payment into the wrong ERNDIM bank account, will be borne by the participant. ERNDIM is responsible solely for paying its own bank charges. Any other charges related to invoice payments must be paid by the participant.

<u>All</u> correspondence and invoice payments <u>MUST</u> contain your laboratory's ERNDIM reference number (ERNxxxx) otherwise it may not be possible to match the payment to the correct account.

ERNDIM bank accounts.

For payments in <u>Euros</u> please use:

STICHING ERNDIM QAP Barclays Bank PLC, SHEFFIELD CITY, Leicester, LE87 2BB, UK Account Number: 65615322 Sort Code: 20-76-89 SWIFT Address: BUKBGB22 IBAN: GB76 BUKB20768965615322

For payments in <u>GB Pounds</u> please use:

STICHING ERNDIM QAP Barclays Bank PLC, SHEFFIELD CITY, Leicester, LE87 2BB, UK Account Number: 70540900 Sort Code: 20-76-89 SWIFT Address: BUKBGB22 IBAN: GB59 BUKB20768970540900

For payments in <u>US Dollars</u> please use:

STICHING ERNDIM QAP Barclays Bank PLC, SHEFFIELD CITY, Leicester, LE87 2BB, UK Account Number: 44300511 Sort Code: 20-76-89 SWIFT Address: BUKBGB22 IBAN: GB40 BUKB20768944300511

 ERNDIM only accepts payments by <u>cheque or</u> <u>bank draft in GB Pounds.</u> If paying by cheque or bank draft in GBP, it should be made payable to 'ERNDIM' and sent to:

ERNDIM Administration Office, c/o EMQN CIC, Unit 4, Enterprise House, Manchester Science Park, Pencroft Way, Manchester, M15 6SE, United Kingdom FRNDIM

6. Terms and Conditions of EQA Scheme Participation for Participating Centres

Use of data derived from ERNDIM EQA Materials

1. Data derived from the use or analysis of ERNDIM EQA materials **must not be** used in written publications or oral presentations unless the explicit prior consent of ERNDIM has been granted.

- If a participating laboratory wishes to use such data in a publication or presentation, they <u>must</u> contact the ERNDIM Administration Office before submitting any documents for publication.
- 2. For EQA materials based on real clinical samples, permission to use the data will be dependent on the appropriate consent being in place.
- If permission to use the data is granted: a) ERNDIM must be acknowledged in the publication or presentation using a standard acknowledgement sentence which will be provided by the ERNDIM Administration Office, and b) after the data has been published a copy of the publication, with full reference/citation information, should be sent to the ERNDIM Administration Office.

Registering for EQA Schemes

2. When registering for ERNDIM EQA schemes it is the responsibility of the person listed as the laboratory primary contact to provide the ERNDIM Administration office with valid, up to date contact and address details, which should include:

- 1. Email and postal addresses for a primary and secondary contact persons* (these contacts will be used for all routine ERNDIM correspondence)
- Email address for named Head of Laboratory or Quality Manager* (this contact will only be used in certain cases of poor performance or if the primary and secondary persistently do not respond to ERNDIM correspondence)
- 3. A postal address for the registering Laboratory
- 4. A delivery address for EQA materials
- 5. An invoice address and named invoice contact with email address
- * these contact details must be for **3 different people**

Any subsequent change in contact persons or address details **must** be sent to the ERNDIM Administration Office as soon as possible.

3. Participants are responsible for ensuring that they have obtained any import or other permits required for delivery of the EQA materials and for sending these to the ERNDIM Administration office during the Registration period.

4. Mailing charges (per scheme) will be added to the EQA order unless the participant provides the details of a courier account to be used for the sample dispatch. Any additional customs charges will be paid by the participant.

5. For participants that submit an EQA scheme order by the Registration deadline, invoices will be sent out in November/December and will be dated 1st January of the following year, as requested by a number of laboratories.

Invoices and Payments

6. If your hospital or laboratory procedures require a Purchase Order number on the invoice, this should be added to the registration form.

7. Invoices will be sent by email only to the primary, secondary and invoice contacts for each laboratory. It is the responsibility of the primary laboratory contact to provide a valid invoice address, invoice contact name and invoice email address.

8. The participant **must** check the information in the invoice. If all details are correct the invoice should be passed for payment to the appropriate finance department. If any details on the invoice are not correct the ERNDIM Administration office (admin@erndim.org) should be notified by mid-December and a revised invoice will be issued.

9. The invoice payment date will be stated on the invoice but for orders submitted within the registration period, **invoice payments must be received by ERNDIM by 1st April in the scheme year**, unless an earlier date (due to late payment of a previous invoice) or later date (due to late registration) is specified.

10. For participants that submit a late registration request any invoices will be dated with the issued date and the payment date will be 1st April or 8 weeks from the issued date, whichever is later.

11. It is the responsibility of the participant laboratory to ensure that the ERNDIM invoice is paid.

12. ERNDIM accepts payments in Euro, GB pounds or US dollars and it is important that the correct bank account is used for payments in each currency. Payments which are made into the wrong bank account (for example a payment in Euros paid into the GB pounds account) can result in losses due to the bank exchange rate. Any losses which are a result of a participant making a payment into the wrong ERNDIM bank account will be borne by the participant.

13. ERNDIM is responsible solely for paying its own bank charges. Any other charges related to invoice payments must be paid by the participant.

14. Penalties for late payment of invoices are:

- Interest charges of 1.3% per month are applied to outstanding balances after the invoice payment date. When interest is added to the outstanding balance an updated invoice with a new version number will be generated;
- If there is still an outstanding invoice balance after the 1st July, in the following year the invoice payment date of any invoices will be 31st January and the dispatch of samples to the laboratory in the that year will be delayed until ALL outstanding invoices have been paid;
- If there is still an outstanding invoice balance after the 1st August, access to the EQA scheme results will be restricted until the invoice has been paid;
- 4. If there is still an outstanding invoice balance after the 1st September, in the same year as the scheme participation, the laboratory will not be eligible to register for any ERNDIM EQA schemes until all outstanding invoices have been paid and a Certificate of Participation for the current scheme year will not be issued.

EQA Scheme Participation

15. EQA samples must be treated in the same way as clinical samples.

16. Compliance with the EQA submission deadlines is a requirement of satisfactory participation in the EQA schemes.

- 1. Requests for late submissions will only be allowed under **exceptional** circumstances and as such requests for late submission on more than one occasion will not routinely be accepted.
- 2. No late/amended results can be accepted if the relevant consensus results or diagnoses have already been published.

17. Participants must not collude with other laboratories on the results of their EQA scheme participation. This includes the use of cluster labs unless these are specifically allowed in the individual EQA scheme (e.g. DPT scheme).

- Laboratories which have been found to have colluded and/or falsified results will be excluded from participating in future EQA schemes and where necessary, the relevant competent authority will be notified.
- In cases where collusion is strongly suspected, ERNDIM reserves the right to withhold the certificate of participation for the specified scheme year from the relevant laboratories and may also exclude the laboratories from participating in future EQA schemes.

18. All participating laboratories are given a unique ERNDIM reference number which should be used on all invoice payments and in all correspondence with ERNDIM.

19. The fact that your laboratory participates in ERNDIM schemes is not confidential, however, the raw data and performance scores are confidential and will only be shared within ERNDIM for the purpose of evaluating your laboratory's performance, (which may include sharing information between the ERNDIM schemes that you subscribe to) except in these circumstances:

- 1. Performance information of United Kingdom laboratories is shared with NQAAP.
- If ERNDIM is approached by other equivalent national bodies, ERNDIM may share performance information with those bodies, but in that case the labs concerned would be informed in advance. For countries with fewer than 5 participating laboratories, to preserve anonymity, only regional data will be shared.

Performance Evaluation

20. Satisfactory performance in an EQA scheme is based solely on the laboratory's performance when analysing the QA samples supplied in that scheme year. By participating in ERNDIM schemes participants agree to these terms and conditions. Performance assessment of scheme participation is described in the ERNDIM quality documents (available on request).

21. ERNDIM is not responsible for the performance of participating laboratories when offering a clinical diagnostics service.

22. Laboratories that have unsatisfactory performance will be sent a Performance Support Letter by ERNDIM. If a laboratory does not respond to the Performance Support Letter, or has persistent unsatisfactory performance, ERNDIM reserves the right to contact the Laboratory Head or Quality Manager.

23. For laboratories that have unsatisfactory performance in more than one EQA scheme during one scheme year (i.e. Global Poor Performance) ERNDIM reserves the right to contact the Laboratory Head or Quality Manager. For laboratories that have persistent Global Poor Performance ERNDIM reserves the right to contact the CEO or equivalent of the relevant institution.

24. Laboratories that do not submit any results, or do not submit sufficient results for their performance to be evaluated, will be sent a Non-submission letter. If a laboratory does not respond to the Non-submission Letter, or persistently does not submit sufficient results for their performance to be evaluated ERNDIM reserves the right to contact the Laboratory Head or Quality Manager and may restrict eligibility for future scheme years.

ERNDIM

25. If a laboratory does not supply the contact details for the Laboratory Head or Quality Manager, ERNDIM reserves the right to withhold the laboratory's Certificate of Participation until such time as the contact details are supplied.

Data Protection & Privacy

26. Any personal information you supply to ERNDIM via this website will be treated in accordance with the <u>ERNDIM</u> <u>Privacy Policy</u> (which can be found on <u>www.erndim.org</u>) and the UK's Data Protection Act 2018, which is the UK's implementation of the EU General Data Protection Regulation (GDPR) 2016.

27. By using this website, you consent to ERNDIM processing any data you provide in line with the <u>ERNDIM</u> <u>Privacy Policy</u> and confirm that all data provided by you is accurate. If there are any changes to the data you have provided, it is your responsibility to update such data.

Problems & Complaints

28. Problems relating to EQA Schemes, including complaints from participating laboratories should be referred directly to the ERNDIM Administration Office (admin@erndim.org).

Copyright

29. All documents, and the data they contain, issued by ERNDIM are copyright and must **not** be published in any form without the permission of the ERNDIM Executive Committee.